Terms: = Lung cancer AND GATA2, NFE1B, 2624, ENSG00000179348, MGC2306, P23769 AND Treatment
9 results:
1. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.
Rojo-Tolosa S; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; González-Gutiérrez MV; Jiménez-Gálvez G; Pérez-Ramírez C; Morales-García C; Jiménez-Morales A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108192
[TBL] [Abstract] [Full Text] [Related]
2. LINC00891 regulated by miR-128-3p/gata2 axis impedes lung cancer cell proliferation, invasion and EMT by inhibiting RhoA pathway.
Zhang Y; Song D; Peng Z; Wang R; Li K; Ren H; Sun X; Du N; Tang SC
Acta Biochim Biophys Sin (Shanghai); 2022 Mar; 54(3):378-387. PubMed ID: 35538035
[TBL] [Abstract] [Full Text] [Related]
3. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
[TBL] [Abstract] [Full Text] [Related]
4. Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Fujimoto D; Akamatsu H; Morimoto T; Wakuda K; Sato Y; Kawa Y; Yokoyama T; Tamiya M; Hiraoka R; Shingu N; Ikeda H; Tamiya A; Kanazu M; Miyauchi E; Miura S; Yanai M; Yomota M; Morinaga R; Yokoi T; Hata A; Suzuki H; Matsumoto H; Sakata S; Furuya N; Harutani Y; Nakachi I; Otsuki A; Uematsu S; Hara S; Yokoo K; Sugimoto T; Yamamoto N
Eur J Cancer; 2022 May; 166():41-50. PubMed ID: 35278824
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic options for CTLA-4 insufficiency.
Egg D; Rump IC; Mitsuiki N; Rojas-Restrepo J; Maccari ME; Schwab C; Gabrysch A; Warnatz K; Goldacker S; Patiño V; Wolff D; Okada S; Hayakawa S; Shikama Y; Kanda K; Imai K; Sotomatsu M; Kuwashima M; Kamiya T; Morio T; Matsumoto K; Mori T; Yoshimoto Y; Dybedal I; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Lorenz HM; Sullivan KE; Heimall J; Moutschen M; Litzman J; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Snapper S; Giulino-Roth L; Svaton M; Platt CD; Hambleton S; Neth O; Gosse G; Reinsch S; Holzinger D; Kim YJ; Bakhtiar S; Atschekzei F; Schmidt R; Sogkas G; Chandrakasan S; Rae W; Derfalvi B; Marquart HV; Ozen A; Kiykim A; Karakoc-Aydiner E; Králíčková P; de Bree G; Kiritsi D; Seidel MG; Kobbe R; Dantzer J; Alsina L; Armangue T; Lougaris V; Agyeman P; Nyström S; Buchbinder D; Arkwright PD; Grimbacher B
J Allergy Clin Immunol; 2022 Feb; 149(2):736-746. PubMed ID: 34111452
[TBL] [Abstract] [Full Text] [Related]
6. The Influence of Histologic Subtype in Predicting Survival of lung cancer Patients With Spinal Metastases.
Kumar N; Tan KA; Tan JH; Zaw AS; Hey HWD; Ruiz J; Stone E
Clin Spine Surg; 2018 Feb; 31(1):E1-E7. PubMed ID: 27875414
[TBL] [Abstract] [Full Text] [Related]
7. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell lung cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zer A; Ding K; Lee SM; Goss GD; Seymour L; Ellis PM; Hackshaw A; Bradbury PA; Han L; O'Callaghan CJ; Tsao MS; Shepherd FA
J Thorac Oncol; 2016 Mar; 11(3):312-23. PubMed ID: 26749487
[TBL] [Abstract] [Full Text] [Related]
8. Cationic lipid-assisted polymeric nanoparticle mediated gata2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
[TBL] [Abstract] [Full Text] [Related]
9. Abnormal gene expression and gene fusion in lung adenocarcinoma with high-throughput RNA sequencing.
Yang ZH; Zheng R; Gao Y; Zhang Q; Zhang H
Cancer Gene Ther; 2014 Feb; 21(2):74-82. PubMed ID: 24503571
[TBL] [Abstract] [Full Text] [Related]
